Key result
Carvedilol significantly increased parasympathetic activity (ΔHFnu = +0.77) while Metoprolol decreased it (ΔHFnu = -0.08) in patients with type 2 diabetes, indicating Carvedilol has a more profound effect on sympathovagal balance.
Why the study?
Does carvedilol compared to metoprolol differentially affect parasympathetic and sympathetic activity in patients with type 2 diabetes?
Observational (n=147)
Yes
Does carvedilol compared to metoprolol differentially affect parasympathetic and sympathetic activity in patients with type 2 diabetes?
Absolute Event Rate: 0.77% vs -0.08%
p-value: p=<0.010
Carvedilol, unlike metoprolol, increases parasympathetic activity in addition to reducing sympathetic activity, which may contribute to its cardioprotective effects in patients with type 2 diabetes.
Does not support changing beta-blocker selection in type 2 diabetes; leaves open whether carvedilol's autonomic effects improve outcomes.
BACKGROUND: Cardiovascular autonomic neuropathy (CAN) is recognized as a significant health risk. Specific and sensitive measures of CAN are needed for early identification and treatment to avoid complications, preferably in the preclinical state. OBJECTIVES: In this first of two articles, the patient cohort is described and two measures of autonomic function are reviewed: the traditional heart rate variability (HRV)-alone method and the newer parasympathetic and sympathetic (P&S) Method. These systems are then evaluated against known effects of the alpha/beta-adrenergic blocker, Carvedilol, and the selective beta-adrenergic blocker, Metoprolol, on P&S activity. METHODS: Serial autonomic nervous system test data from 147 type 2 diabetes mellitus patients from eight ambulatory clinics were analyzed. Patients were grouped according to whether a beta-blocker was (1) introduced, (2) discontinued or (3) continued without adjustment. Group 3 served as the control. HRV-alone parameters are computed according to standards. The P&S Method, which is a time-frequency analyses of concurrent respiratory activity and HRV, is elucidated, as developed at MIT and Harvard Medical School (1981). RESULTS: The HRV-alone demonstrated that introducing either medication increased low frequency (msec(2)) and standard deviation of the beat-to-beat (N-N) interval (msec), as expected. The other HRV parameter responses were not consistent with expectations. Similar inconsistencies occurred when either medication was discontinued. The P&S Method demonstrated that introducing or discontinuing either agent decreased or increased sympathetic activity, respectively, according to expectations. With ongoing treatment, resting parasympathetic activity decreased with Metoprolol but increased with Carvedilol. CONCLUSION: Autonomic assessment fidelity was significantly higher with the P&S Method as validated by comparison with previously known physiology of the cardiovascular system.
No takes yet. Share an insight, caveat, or question.
Vinik et al. (2014) conducted an observational in Type 2 diabetes mellitus (n=147). Carvedilol vs. Metoprolol was evaluated on Change in normalized high frequency (ΔHFnu) measure representing parasympathetic tone with continued therapy (p=<0.010). Carvedilol significantly increased parasympathetic activity (ΔHFnu = +0.77) while Metoprolol decreased it (ΔHFnu = -0.08) in patients with type 2 diabetes, indicating Carvedilol has a more profound effect on sympathovagal balance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: